Высокая частота распространения вируса папилломы человека и большой риск рецидивирования ассоциированных заболеваний требуют поиска эффективных методов терапии. Проведен анализ качественных клинических исследований, результированы данные об эффективности, переносимости лечения. Собственное исследование демонстрирует более высокую эффективность деструктивных методов в сочетании с системным применением препарата Изопринозин. Даже в режиме монотерапии эффективность Изопринозина достигает 68%.
Ключевые слова: вирус папилломы человека, лечение, иммуномодуляторы, Изопринозин.
________________________________________________
The high frequency of the spread of human papillomavirus and a high risk of recurrence associated diseases require the search for effective therapies. The analysis of quality clinical trials showed data on the efficacy, tolerability of treatment. Our study demonstrates higher efficiency destructive methods in conjunction with the system using Isoprinosine. Even Isoprinosine mono therapy's efficiency reaches 68%.
Key words: human papillomavirus, therapy, immunomodulators, Isoprinosine.
1. Прилепская В.Н., Рудакова Е.Б. Генитальные инфекции и патология шейки матки. Клинические лекции. Омск: ИПЦ ОмГМА, 2004. / Prilepskaia V.N., Rudakova E.B. Genital'nye infektsii i patologiia sheiki matki. Klinicheskie lektsii. Omsk: IPTs OmGMA, 2004. [in Russian]
2. Прилепская В.Н. Заболевания шейки матки, влагалища и вульвы. М.: МЕДпресс-информ, 2005. / Prilepskaia V.N. Zabolevaniia sheiki matki, vlagalishcha i vul'vy. M.: MEDpress-inform, 2005. [in Russian]
3. Прилепская В.Н. Вирус папилломы человека: современный взгляд на проблему. Мед. вестн. 2007; 29 (414): 9–10. / Prilepskaia V.N. Virus papillomy cheloveka: sovremennyi vzgliad na problemu. Med. vestn. 2007; 29 (414): 9–10. [in Russian]
4. Рудакова Е.Б. Псевдоэрозии шейки матки. Автореф. дис. … д-ра мед. наук. Омск, 1996. / Rudakova E.B. Psevdoerozii sheiki matki. Avtoref. dis. … d-ra med. nauk. Omsk, 1996. [in Russian]
5. Роговская С.И., Прилепская В.Н. Оптимизация лечения хронических цервицитов с помощью изопринозина. Гинекология. 2006; 8 (1): 4–7. / Rogovskaia S.I., Prilepskaia V.N. Optimizatsiia lecheniia khronicheskikh tservitsitov s pomoshch'iu izoprinozina. Ginecology. 2006; 8 (1): 4–7.
6. Chen JN, Chen LD, Zhang WY et al. Epidemiological survey of high-risk human papillomavirus among 2501 woman. Nan Fang Yi Ke Da Xue Xue Bao 2015; 35 (10): 1487–91.
7. Cheng J, Bian M, Cong X et al. Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening. Biomed Rep 2013; 1 (2): 280–4.
8. Globocan. Cancer incidence, mortality and prevalence world wide. Last access 25.01.2007.IARC WHU Press Release 151 IARC confirms efficacy of cervix cancer screening for women 25–65 in reducing mortality, 03 May 2004.
9. Donders G, Parent D. HPV. Questions & Answers. Benign genital HPV infections. Int. Edition. Artoos Communicatie group NV 2010.
10. Nejmark BA, Kondrat'eva JS, Zologina VS, Torbik DV. Effectiveness of combined treatment of HPV infection. Urologiia 2015; 2: 39–40, 42.
11. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24 (Suppl. 3): 11–25.
12. Rintala MA, Grenman SE, Jarvenkyla ME et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005; 41: 1728–33.
13. Virtanen A, Anttila A, Nieminen P. The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland. BMC Womens Health 2015; 15 (1): 99.
14. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization, 2013.
________________________________________________
1. Prilepskaia V.N., Rudakova E.B. Genital'nye infektsii i patologiia sheiki matki. Klinicheskie lektsii. Omsk: IPTs OmGMA, 2004. [in Russian]
2. Prilepskaia V.N. Zabolevaniia sheiki matki, vlagalishcha i vul'vy. M.: MEDpress-inform, 2005. [in Russian]
3. Prilepskaia V.N. Virus papillomy cheloveka: sovremennyi vzgliad na problemu. Med. vestn. 2007; 29 (414): 9–10. [in Russian]
4. Rudakova E.B. Psevdoerozii sheiki matki. Avtoref. dis. … d-ra med. nauk. Omsk, 1996. [in Russian]
5. Rogovskaia S.I., Prilepskaia V.N. Optimizatsiia lecheniia khronicheskikh tservitsitov s pomoshch'iu izoprinozina. Ginecology. 2006; 8 (1): 4–7.
6. Chen JN, Chen LD, Zhang WY et al. Epidemiological survey of high-risk human papillomavirus among 2501 woman. Nan Fang Yi Ke Da Xue Xue Bao 2015; 35 (10): 1487–91.
7. Cheng J, Bian M, Cong X et al. Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening. Biomed Rep 2013; 1 (2): 280–4.
8. Globocan. Cancer incidence, mortality and prevalence world wide. Last access 25.01.2007.IARC WHU Press Release 151 IARC confirms efficacy of cervix cancer screening for women 25–65 in reducing mortality, 03 May 2004.
9. Donders G, Parent D. HPV. Questions & Answers. Benign genital HPV infections. Int. Edition. Artoos Communicatie group NV 2010.
10. Nejmark BA, Kondrat'eva JS, Zologina VS, Torbik DV. Effectiveness of combined treatment of HPV infection. Urologiia 2015; 2: 39–40, 42.
11. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24 (Suppl. 3): 11–25.
12. Rintala MA, Grenman SE, Jarvenkyla ME et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005; 41: 1728–33.
13. Virtanen A, Anttila A, Nieminen P. The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland. BMC Womens Health 2015; 15 (1): 99.
14. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization, 2013.
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*pbumer@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow,
ul. Trubetskaia, d. 8, str. 2
*pbumer@mail.ru